Werewolf Therapeutics, Inc.

NasdaqGS:HOWL 주식 보고서

시가총액: US$84.7m

Werewolf Therapeutics 관리

관리 기준 확인 3/4

Werewolf Therapeutics CEO는 Dan Hicklin, Oct2017 에 임명되었습니다 의 임기는 7.08 년입니다. 총 연간 보상은 $ 1.37M, 42.7% 로 구성됩니다. 42.7% 급여 및 57.3% 보너스(회사 주식 및 옵션 포함). 는 $ 1.23M 가치에 해당하는 회사 주식의 1.45% 직접 소유합니다. 1.23M. 경영진과 이사회의 평균 재임 기간은 각각 3.9 년과 5.1 년입니다.

주요 정보

Dan Hicklin

최고 경영자

US$1.4m

총 보상

CEO 급여 비율42.7%
CEO 임기7.1yrs
CEO 소유권1.5%
경영진 평균 재임 기간3.9yrs
이사회 평균 재임 기간5.1yrs

최근 관리 업데이트

Recent updates

Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?

Nov 14
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Jul 31
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jul 01

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

CEO 보상 분석

Dan Hicklin 의 보수는 Werewolf Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$54m

Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$1mUS$583k

-US$37m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$2mUS$530k

-US$54m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$115m

Dec 31 2021US$2mUS$498k

-US$202m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$197m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$3mUS$425k

-US$28m

보상 대 시장: Dan 의 총 보상 ($USD 1.37M )은 US 시장( $USD 649.07K ).

보상과 수익: Dan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dan Hicklin (60 yo)

7.1yrs

테뉴어

US$1,366,904

보상

Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...

리더십 팀

이름위치테뉴어보상소유권
Daniel Hicklin
Founder7.1yrsUS$1.37m1.45%
$ 1.2m
Timothy Trost
CFO, Treasurer & Assistant Secretary3.8yrsUS$815.59k0%
$ 0
Randi Isaacs
Chief Medical Officer4yrsUS$855.77k0%
$ 0
William Winston
Senior Vice President of Researchless than a year데이터 없음데이터 없음
Chulani Karunatilake
Chief Technology Officer3.4yrsUS$3.86m데이터 없음
Ellen Lubman
Chief Business Officer4.3yrs데이터 없음데이터 없음

3.9yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 관리: HOWL 의 관리팀은 경험 ( 3.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Daniel Hicklin
Founder7.1yrsUS$1.37m1.45%
$ 1.2m
Luke Evnin
Independent Chairman of the Board7.1yrsUS$104.03k0%
$ 0
Michael Sherman
Independent Director3.5yrsUS$78.66k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Vijay Kuchroo
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Briggs W. Morrison
Independent Director5yrsUS$62.32k0.035%
$ 29.5k
Karl Wittrup
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Atkins
Member of Scientific Advisory Board & Director6.3yrs데이터 없음0.032%
$ 27.4k
Alon Lazarus
Independent Director5.3yrsUS$78.53k4.59%
$ 3.9m
Meeta Chatterjee
Independent Director3.1yrsUS$65.36k0%
$ 0
Derek DiRocco
Independent Director3.9yrsUS$72.53k0%
$ 0
Dario Vignali
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

5.1yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: HOWL 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.